Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QX027N injection in adults with chronic rhinosinusitis with nasal polyps
CTR20263879Phase 2Active
- Sponsor
- Quxin Biopharmaceutical
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QX027N in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Quxin Biopharmaceutical. Started Oct 2026; status: active.
02
Drugs
QX027N
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20263879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263879.